Sale!

STELFONTA (tigilanol tiglate injection) 1mg/ml Vial (2ml)

Name: STELFONTA (tigilanol tiglate injection) 1mg/ml Vial (2ml)
Brand: Stelfonta
SKU: 64529
Price: 639.99 USD
Availability: InStock
Rating: 0 (0 reviews)

Original price was: $ 657.99.Current price is: $ 639.99.

(0 customer reviews)

Prescription(s) Required

We’ll collect your pet information to verify this prescription with your veterinarian before shipping. Your prescription order will ship upon veterinarian approval.

This item is specially packaged to remain refrigerated during transit. 1-2 Day Air Refrigerated Shipping Only OR Local Pickup. Does not Qualify for Free Shipping.

STRENGTH/SIZE

QUANTITY

Clear

Categories: Dog Cancer Medications, Dog Immunosuppressives Tag: Cancer Medications Brand: Stelfonta Brand: Stelfonta

Description

Description

STELFONTA^® (tigilanol tiglate injection) is an intratumoral injection indicated for use in dogs for the local treatment of MCTs that are:

non-metastatic cutaneous mast cell tumors
non-metastatic subcutaneous mast cell tumors located at or distal to the elbow or the hock

Uses

STELFONTA injection is indicated for use in dogs for the treatment of:

non-metastatic cutaneous mast cell tumors
non-metastatic subcutaneous mast cell tumors located at or distal to the elbow
or the hock

For more information please visit https://vet-us.virbac.com/stelfonta#stelfontareg-indication

Additional information

Weight	N/A
Dimensions	N/A
STRENGTH/SIZE	1mg/ml
QUANTITY	1 Vial.
Administration	WARNING: SEVERE WOUND FORMATION IN HUMANS; EXTENSIVE WOUND FORMATION, MAST CELL DEGRANULATION, AND DEATH IN DOGS DUE TO MAST CELL DEGRANULATION Human Safety • Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental selfinjection, sedation of the dog may be necessary (see Dosage and Administration, Human Warnings and Adverse Reactions). Dog Safety • Always administer a corticosteroid (e.g. prednisone or prednisolone), an H1 receptor blocking agent (e.g. diphenhydramine), and an H2 receptor blocking agent (e.g. famotidine) when treating with STELFONTA to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation (see Contraindications and Dosage and Administration). • Do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock (e.g. on the body, head, or neck). This may result in accumulation of necrotic debris in the subcutaneous space increasing the risk of systemic adverse reactions, including death, from mast cell degranulation (see Contraindications, Warnings and Adverse Events). • Treatment with STELFONTA has been associated with cellulitis and severe tissue sloughing extending away from the treated site resulting in extensive wounds that require additional treatment and prolonged recovery times (see Warnings, Precautions and Adverse Events).
INFORMATION FOR DOG OWNERS	Owners should be given the Client Information Sheet to read before STELFONTA is administered and should be advised to observe their dog for potential side effects, including signs of degranulation and excessive wound formation, as described in the sheet. Advise dog owners about possible adverse reactions, when to contact a veterinarian, and how to care for the treated tumor site. Some discharge from the site following treatment is expected. The site can be cleaned with warm water as necessary. Advise owners to wear disposable gloves when cleaning the area.
Storage Instructions	Store STELFONTA vials refrigerated at 2°C to 8°C (35°F to 46°F). Do not freeze. Keep the vial in the carton at all times to protect the vial from light. For single use only. Dispose of any unused product in accordance with disposal for routine medical waste
CONTRAINDICATIONS	Do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock (e.g. on the body, head, or neck). This may result in accumulation of necrotic debris in the subcutaneous space increasing the risk of systemic adverse reactions, including death, from mast cell degranulation
WARNINGS	Human Safety NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN. Caution is required during treatment to avoid accidental self-injection. Dogs undergoing treatment with STELFONTA should be adequately restrained and sedation used if necessary. Use a Luer-lock syringe to administer STELFONTA. Do not recap the needle. Accidental self-injection may result in local inflammatory reactions, including swelling, redness and severe wound formation. In case of accidental self-injection, immediately rinse the area with water, seek medical advice immediately, and show the package insert to the physician. Wear personal protective equipment consisting of disposable gloves, protective eye wear, and a lab coat or gown when handling STELFONTA. STELFONTA is an irritant and accidental exposure to skin, eye, or by ingestion should be avoided. In case of dermal or ocular exposure, repeatedly wash the exposed skin or eye with water. If wearing contacts, rinse the eyes first then remove contacts and continue to rinse with water. If symptoms such as local signs of redness and swelling occur, or if there has been ingestion, seek the advice of a physician and show them the package insert. Limited data is available on the potential teratogenic effects of STELFONTA. Therefore, STELFONTA should not be administered by women who are pregnant or planning to become pregnant. People with known hypersensitivity to tigilanol tiglate or to any of the excipients should avoid contact with STELFONTA.